Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.47 |
| ▸ | TLR2 | O60603 | 1/20 | 0.40 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.39 |
| ▸ | ALB | P02768 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.37 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26972994 | 0.91 | GLP1R (0.46) | GLP1RTLR2NOD1ALBFOLH1 | |
| SCHEMBL26369521 | 0.90 | GLP1R (0.47) | GLP1RTLR2NOD1ALBFOLH1 | |
| SCHEMBL26514321 | 0.90 | GLP1R (0.47) | GLP1RTLR2NOD1ALBFOLH1 | |
| SCHEMBL12659447 | 0.86 | TP53 (0.39) | GLP1RHPGDHTTSMN1; SMN2 | |
| SCHEMBL22223488 | 0.86 | GLP1R (0.57) | GLP1RTLR2FOLH1EPHX2SIRT2 | |
| SCHEMBL25920623 | 0.86 | TLR2 (0.37) | GLP1RTLR2NOD1ALBFOLH1 | |
| SCHEMBL13753618 | 0.85 | GLP1R (0.51) | GLP1RTLR2NOD1ALBFOLH1 | |
| SCHEMBL25825650 | 0.85 | GLP1R (0.51) | GLP1RTLR2NOD1ALBFOLH1 | |
| SCHEMBL22223529 | 0.84 | NOD1 (0.42) | TLR2NOD1FOLH1EPHX2 | |
| SCHEMBL19703480 | 0.81 | CASP2 (0.40) | EPHX2HPGDHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230248836-A1 | Dosage Regimen for a Controlled-Release PTH Compound | ASCENDIS PHARMA BONE DISEASES A/S (DK) | 2023-08-10 | — | — | US | disclosed |
| US-20230218722-A1 | PTH Compounds with Low Peak-To-Trough Ratios | ASCENDIS PHARMA BONE DISEASES AS (DK) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230248836-A1 | Dosage Regimen for a Controlled-Release PTH Compound | PTH1R, CALCA, CALCR | GLP1R 107/4885TLR2 4017/4885NOD1 1187/4885 |
| US-20230218722-A1 | PTH Compounds with Low Peak-To-Trough Ratios | PTH1R, PTMS, FGF23 | GLP1R 10/4885TLR2 3753/4885NOD1 3030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.